Contributions
Abstract: EP1550
Type: ePoster
Abstract Category: Therapy - disease modifying - Others
Objective: Adherence to disease modifying therapy (DMT) in patients with multiple sclerosis (MS) is needed to achieve optimal clinical benefit. Improved understanding of factors that impact DMT adherence may help to guide effective interventions. Thus, the objective of this study was to examine the associations between treatment satisfaction, medication beliefs and adherence to DMT through a survey.
Methods: A paper-pencil survey was mailed in March 2016 to 600 adult patients with a relapsing form of MS taking an injectable or oral DMT. Patients were sampled from the North American Research Committee on Multiple Sclerosis (NARCOMS) patient registry. The survey measured self-reported DMT adherence (i.e., doses taken divided by doses prescribed over the last two-week period) with adherence categorized as ≥0.80, satisfaction with DMT (effectiveness, side effects, convenience, and global) using the Treatment Satisfaction Questionnaire for Medication version II (TSQM vII), medication beliefs (perceived necessity and perceived concern) using the Beliefs about Medicines Questionnaire (BMQ), and demographic (i.e., age, race, marital status, education, insurance) and clinical (i.e., MS duration, DMT duration, type of DMT) covariates. All variables were entered simultaneously in a multivariate logistic regression model.
Results: Of 600 surveys mailed, 478 (79.7% response rate) were included in the analyses. Most respondents were white (93.7%), female (86.5%), and taking an injectable DMT (66.5%). Their mean age was 60.6±8.4 years and most were adherent to DMT (92.9%). In the logistic regression model, significant predictors of DMT adherence were type of DMT (oral versus injectable [reference]) (OR=17.7, 95% CI: 1.2-261.4, p=0.037) and age (OR=1.1, 95% CI: 1.006-1.162, p=0.034).
Conclusion: Treatment satisfaction and medication beliefs were not significantly associated with DMT adherence. However, age and type of DMT were positive predictors, suggesting that younger patients and patients taking injectable DMTs are at higher risk for nonadherence.
Disclosure: Andrew Thach: received research funding from Novartis Pharmaceuticals Corporation
Carolyn Brown: received research funding from Novartis Pharmaceuticals Corporation
Vivian Herrera: employee of Novartis Pharmaceuticals Corporation
Rahul Sasane: employee of Novartis Pharmaceuticals Corporation
Jamie Barner: nothing to disclose
Kenneth Lawson: received research funding from Novartis Pharmaceuticals Corporation for a different research project
Kentya Ford: nothing to disclose
Abstract: EP1550
Type: ePoster
Abstract Category: Therapy - disease modifying - Others
Objective: Adherence to disease modifying therapy (DMT) in patients with multiple sclerosis (MS) is needed to achieve optimal clinical benefit. Improved understanding of factors that impact DMT adherence may help to guide effective interventions. Thus, the objective of this study was to examine the associations between treatment satisfaction, medication beliefs and adherence to DMT through a survey.
Methods: A paper-pencil survey was mailed in March 2016 to 600 adult patients with a relapsing form of MS taking an injectable or oral DMT. Patients were sampled from the North American Research Committee on Multiple Sclerosis (NARCOMS) patient registry. The survey measured self-reported DMT adherence (i.e., doses taken divided by doses prescribed over the last two-week period) with adherence categorized as ≥0.80, satisfaction with DMT (effectiveness, side effects, convenience, and global) using the Treatment Satisfaction Questionnaire for Medication version II (TSQM vII), medication beliefs (perceived necessity and perceived concern) using the Beliefs about Medicines Questionnaire (BMQ), and demographic (i.e., age, race, marital status, education, insurance) and clinical (i.e., MS duration, DMT duration, type of DMT) covariates. All variables were entered simultaneously in a multivariate logistic regression model.
Results: Of 600 surveys mailed, 478 (79.7% response rate) were included in the analyses. Most respondents were white (93.7%), female (86.5%), and taking an injectable DMT (66.5%). Their mean age was 60.6±8.4 years and most were adherent to DMT (92.9%). In the logistic regression model, significant predictors of DMT adherence were type of DMT (oral versus injectable [reference]) (OR=17.7, 95% CI: 1.2-261.4, p=0.037) and age (OR=1.1, 95% CI: 1.006-1.162, p=0.034).
Conclusion: Treatment satisfaction and medication beliefs were not significantly associated with DMT adherence. However, age and type of DMT were positive predictors, suggesting that younger patients and patients taking injectable DMTs are at higher risk for nonadherence.
Disclosure: Andrew Thach: received research funding from Novartis Pharmaceuticals Corporation
Carolyn Brown: received research funding from Novartis Pharmaceuticals Corporation
Vivian Herrera: employee of Novartis Pharmaceuticals Corporation
Rahul Sasane: employee of Novartis Pharmaceuticals Corporation
Jamie Barner: nothing to disclose
Kenneth Lawson: received research funding from Novartis Pharmaceuticals Corporation for a different research project
Kentya Ford: nothing to disclose